Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report.
Giorgio, A., Valeria, C., Annamaria, T., Annunziata, N., & Paolo, U.G. (2026). Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report.. Eur Heart J Case Rep. https://doi.org/10.1093/ehjcr/ytag220
Giorgio A, Valeria C, Annamaria T, Annunziata N, Paolo UG. Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report.. Eur Heart J Case Rep. 2026; doi: 10.1093/ehjcr/ytag220
Giorgio A, Valeria C, Annamaria T, et al. Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report.[J]. Eur Heart J Case Rep. 2026. DOI: 10.1093/ehjcr/ytag220.
@article{giorgio2026,
author = {Antonelli Giorgio and Cammalleri Valeria and Tavernese Annamaria and Nusca Annunziata and Ussia Gian Paolo},
title = {Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report.},
journal = {Eur Heart J Case Rep},
year = {2026},
doi = {10.1093/ehjcr/ytag220},
note = {PMID: 42006590},
}
TY - JOUR AU - Antonelli Giorgio AU - Cammalleri Valeria AU - Tavernese Annamaria AU - Nusca Annunziata AU - Ussia Gian Paolo TI - Valve-in-valve transcatheter pulmonary valve replacement in carcinoid heart disease: a case report. T2 - Eur Heart J Case Rep PY - 2026 DO - 10.1093/ehjcr/ytag220 AN - PMID:42006590 ER -
Carcinoid heart disease (CHD) commonly affects right-sided heart valves, often leading to progressive right heart failure (RHF) and structural valve deterioration. A 30-year-old male with CHD and prior bioprosthetic tricuspid and pulmonic valve replacements presented with New York Heart Association Class III symptoms and RHF. Imaging revealed significant degeneration of both valves. Given the high surgical risk (EuroSCORE II 9.12%), the Heart Team opted for transcatheter pulmonary valve replacement (TPVR). Despite challenging anatomy, a Melody valve (Medtronic) was successfully implanted, resulting in improved haemodynamics and no significant residual regurgitation. Bioprosthetic failure in CHD poses significant treatment challenges. This case underscores the growing role of TPVR as a less invasive and effective alternative to surgery in high-risk patients, with advanced imaging playing a pivotal role in planning and execution.